ISDA: 5HM0

Deposition Date 2016-01-15

Release Date 2016-02-10

Last Version Date 2023-09-27

Entry Detail

PDB ID:

5HM0

Keywords:

TRANSCRIPTION

Title:

Crystal structure of the first bromodomain of human BRD4 bound to benzoisoxazoloazepine 3

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.40 Å

R-Value Free:

0.22

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 4
Gene (Uniprot):BRD4
Chain IDs:A
Chain Length:128
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:O60885 Pfam ID:PF00439

Ligand Molecules

62V

Primary Citation

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.

Albrecht, B.K, Gehling, V.S, Hewitt, M.C, Vaswani, R.G, Cote, A, Leblanc, Y, Nasveschuk, C.G, Bellon, S, Bergeron, L, Campbell, R, Cantone, N, Cooper, M.R, Cummings, R.T, Jayaram, H, Joshi, S, Mertz, J.A, Neiss, A, Normant, E, O'Meara, M, Pardo, E, Poy, F, Sandy, P, Supko, J, Sims, R.J, Harmange, J.C, Taylor, A.M, Audia, J.E.Show

J.Med.Chem. 59 1330 1339 (2016)

PMID: 26815195 DOI: 10.1021/acs.jmedchem.5b01882

Abstact

In recent years, inhibition of the interaction between the bromodomain and extra-terminal domain (BET) family of chromatin adaptors and acetyl-lysine residues on chromatin has emerged as a promising approach to regulate the expression of important disease-relevant genes, including MYC, BCL-2, and NF-κB. Here we describe the identification and characterization of a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor that attenuates BET-dependent gene expression in vivo, demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model, and is currently undergoing human clinical trials for hematological malignancies (CPI-0610).

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form